Barry Quart, Heron Therapeutics CEO
September 19, 2022 02:37 PM EDT
Pharma
FDA+

Heron se­cures FDA ap­proval af­ter R&D head count chop

Paul Schloesser

Associate Editor

The FDA just gave Heron Ther­a­peu­tics a win for its post-surgery nau­sea and vom­it­ing drug — and its fourth ap­proval so far.

The San Diego biotech …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Why did Eli Lil­ly ask a pa­tient on a com­pound­ed GLP-1 drug for their med­ical in­for­ma­tion?

Biotech VC firm out­lines plans for $100M fund

No­vo says its CB1 drug helped shed weight, but ef­fi­ca­cy and safe­ty ques­tions re­main

FDA OKs the first-ever self-ad­min­is­tered vac­cine, for flu

FTC to sue ma­jor PBMs over in­sulin re­bates, claim­ing they in­flat­ed pa­tient cost

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times